Welcome to Multibagg AI
Log in to access personalized features
Discovery themes featuring this stockGet instant AI-powered insights about company performance, financials, and strategy. Ask questions about trends, competition, and developments while receiving responses backed by official documents and market data, with clear attribution to source documents.
Home
Dashboard
Ask Iris
Discovery
Timeline
Multibagg AI is an AI powered stock research and analysis platform. We provide data, information, content, and analytics for publicly traded Indian companies listed on NSE and BSE. AI can make mistakes, check important information.
Prices might be delayed by a few minutes.
Join our Exclusive Community
Join our Exclusive Community
Made with 💙 in India. © Finsky Technologies Pvt Ltd. 2026
Discover detailed, AI-driven financial summaries that break down key metrics, trends, and insights—empowering you to make smarter investment decisions.
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
View Standalone
Investor Presentation
Q3 FY26
Investor Presentation
Q2 FY26
Investor Presentation
Q4 FY25
Available on Pro Plan
Unlock reports, presentations, and AI-powered insights.
Chandan Healthcare Ltd (CHANDAN) is currently trading at 254.00 per share. Stock prices fluctuate during market hours on NSE and BSE based on demand, company updates, and overall market conditions. Refer to the live price chart above for the most recent price movement.
Chandan Healthcare Limited operates an integrated diagnostics, radiology and retail pharmacy network primarily across North and Central India, running company-owned labs and diagnostic centres with NABL/NABH accreditations and a digital front-end called Chandan 24x7 for appointments, e-pharmacy and patient records. In Q3 FY26 Chandan reported consolidated Total Income of ₹65.77 crore (up ~20% YoY) and EBITDA of ₹12.61 crore with a 263 bps expansion in EBITDA margin to 19.17%; nine‑month results show sustained improvement with 9M FY26 Total Income ₹203.27 crore and EBITDA margin rising to 20.95%. The company has completed a preferential issuance raising ~₹104.13 crore (44,50,000 warrants at ₹234 each) with participation from promoter and strategic investors; proceeds are earmarked for ₹44.50 crore of expansion capex and ₹50 crore for acquisitions, materially funding the three‑year roll-out plan. Chandan is aggressively scaling: target to build ~100 labs across 17 states and onboard 1,000 franchise collection points in three years, while already securing a large multi‑year government PPP radiology contract in Punjab and an exclusive five‑year diagnostics tie-up with Jeena Sikho Lifecare that provides meaningful recurring volumes. Customer engagement levers include a loyalty programme with 40 lakh+ cardholders and a digital app with 100k+ downloads; complementary pharmacy revenues (~46% of FY25 revenue) provide cross‑sell opportunities and improved lifetime value in target Tier 2/3 markets where Chandan emphasises affordability and local leadership.
Over the past 52 weeks, Chandan Healthcare Ltd has traded between a low of ₹150.30 and a high of ₹358.00. The 52-week high and low indicate the stock’s price range over the last year and help investors understand its volatility and recent trading levels.
Chandan Healthcare Ltd has a market capitalization of approximately 612.89. Market capitalization represents the total value of a company’s outstanding shares and helps investors understand its size, stability, and relative risk compared to other listed companies.
Chandan Healthcare Ltd’s investment profile depends on its business fundamentals, valuation, and long-term outlook. The stock currently trades at a PE ratio of 23.56 and operates in the Healthcare sector. Investors typically assess financial performance, growth prospects, and individual risk tolerance before making investment decisions.
Based on its market capitalization of 612.89 Cr, Chandan Healthcare Ltd is classified as a Small Cap stock. Large-cap stocks are generally more stable, while mid-cap and small-cap stocks tend to offer higher growth potential along with higher price volatility.
Chandan Healthcare Ltd operates in the Healthcare sector. Sector classification matters because companies in the same sector are often affected by similar economic conditions, regulatory changes, and competitive dynamics, which can influence overall stock performance.
The Price-to-Earnings (PE) ratio of Chandan Healthcare Ltd is 23.56. The PE ratio compares a company’s share price to its earnings and is commonly used to assess valuation. Comparing the PE ratio with sector peers and historical levels provides better context.
Bearish
2
Neutral
6
Bullish
6
Bearish
34
Neutral
6
Bullish
6
Bearish
32
Neutral
0
Bullish
0
| Symbol | Price | Market Cap | P/E | P/B | Div Yield (%) | ROE (%) | ROCE (%) | ROA (%) |
652.00 | 1,181 Cr | 26.00 | 11.66 | 0.00 | 43.51 | 58.07 | 27.58 | |
254.00 | 613 Cr | 23.56 | 4.43 | 0.00 | 18.69 | 20.84 | 10.52 | |
325.00 | 373 Cr | 45.90 | 2.69 | 0.00 | 0.00 | 0.00 | 2.06 | |
65.30 | 112 Cr | 5.53 | 1.09 | 0.00 | 18.49 | 23.03 | 13.19 | |
64.07 | 102 Cr | 7.86 | 1.77 | 0.00 | 43.27 | 33.60 | 13.89 | |
68.10 | 78 Cr | 12.23 | 1.53 | 0.00 | 35.97 | 39.64 | 0.00 | |
55.70 | 61 Cr | 28.27 | 8.47 | 0.00 | 16.62 | 13.17 | 13.75 |
Subsidiary Incorporation
Chandan Healthcare Ltd. announced MCA approval for incorporation of 100%-owned subsidiary Chandan Healthcare Projects Pvt. Ltd. (CIN U86100UP2026PTC245152) on 8 Mar 2026 with authorized capital Rs.15,00,000 and paid-up Rs.1,00,000.
Commencement of Operations
Chandan Healthcare has commenced diagnostic operations in Kurukshetra, Haryana under a five‑year exclusive strategic partnership with Jeena Sikho Lifecare, marking the company’s entry into the state and serving 40 Jeena Sikho locations.
Chandan Healthcare Limited operates an integrated diagnostics, radiology and retail pharmacy network primarily across North and Central India, running company-owned labs and diagnostic centres with NABL/NABH accreditations and a digital front-end called Chandan 24x7 for appointments, e-pharmacy and patient records.
In Q3 FY26 Chandan reported consolidated Total Income of ₹65.77 crore (up ~20% YoY) and EBITDA of ₹12.61 crore with a 263 bps expansion in EBITDA margin to 19.17%; nine‑month results show sustained improvement with 9M FY26 Total Income ₹203.27 crore and EBITDA margin rising to 20.95%.
The company has completed a preferential issuance raising ~₹104.13 crore (44,50,000 warrants at ₹234 each) with participation from promoter and strategic investors; proceeds are earmarked for ₹44.50 crore of expansion capex and ₹50 crore for acquisitions, materially funding the three‑year roll-out plan.
Chandan is aggressively scaling: target to build ~100 labs across 17 states and onboard 1,000 franchise collection points in three years, while already securing a large multi‑year government PPP radiology contract in Punjab and an exclusive five‑year diagnostics tie-up with Jeena Sikho Lifecare that provides meaningful recurring volumes.
Customer engagement levers include a loyalty programme with 40 lakh+ cardholders and a digital app with 100k+ downloads; complementary pharmacy revenues (~46% of FY25 revenue) provide cross‑sell opportunities and improved lifetime value in target Tier 2/3 markets where Chandan emphasises affordability and local leadership.
Healthcare
Diagnostic Services
613 Cr
Low Risk
23.6
41.9
0.5
4.4
358.00
150.30
Sales CAGR
Profit CAGR
ROE
ROCE
